Deutsche Bank Ag\ Cti Biopharma Corp Transaction History

Deutsche Bank Ag\

  • $240 Billion
  • Q3 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$4.2 - $6.01 $78,556 - $112,411
18,704 Added 43.34%
61,859 $259,000
Q4 2022

Feb 13, 2023
BUY
$4.45 - $6.17 $2,945 - $4,084
662 Added 1.56%
43,155 $259,000
Q3 2022

Nov 14, 2022
SELL
$5.36 - $7.43 $9,926 - $13,760
-1,852 Reduced 4.18%
42,493 $247,000
Q2 2022

Aug 11, 2022
BUY
$3.55 - $6.27 $157,403 - $278,005
44,339 Added 738983.31%
44,345 $264,000
Q1 2022

May 13, 2022
SELL
$1.9 - $5.23 $1.84 Million - $5.08 Million
-970,429 Reduced 100.0%
6 $0
Q2 2021

Aug 11, 2021
BUY
$2.16 - $2.62 $2.1 Million - $2.54 Million
970,429 Added 0.0%
970,435 $2.43 Million
Q2 2020

Aug 13, 2020
BUY
$0.88 - $1.32 $5 - $7
6 New
6 $0
Q3 2019

Nov 14, 2019
SELL
$0.64 - $0.92 $44,630 - $64,156
-69,735 Closed
0 $0
Q2 2019

Aug 14, 2019
SELL
$0.8 - $1.03 $35,917 - $46,243
-44,897 Reduced 39.17%
69,735 $58,000
Q1 2019

May 15, 2019
SELL
$0.9 - $1.37 $227,776 - $346,726
-253,085 Reduced 68.83%
114,632 $110,000
Q4 2018

Feb 14, 2019
BUY
$0.73 - $2.19 $174,921 - $524,765
239,619 Added 187.06%
367,717 $269,000
Q3 2018

Dec 21, 2021
BUY
$1.72 - $5.24 $23,118 - $70,430
13,441 Added 11.72%
128,098 $276,000
Q3 2018

Nov 14, 2018
BUY
$1.72 - $5.24 $28,625 - $87,209
16,643 Added 16.98%
114,657 $247,000
Q2 2018

Apr 21, 2020
BUY
$3.81 - $5.26 $63,105 - $87,121
16,563 Added 20.33%
98,014 $488,000
Q2 2018

Aug 14, 2018
BUY
$3.81 - $5.26 $310,263 - $428,342
81,434 Added 479023.53%
81,451 $404,000
Q1 2018

May 15, 2018
SELL
$2.7 - $4.06 $171,730 - $258,232
-63,604 Reduced 99.97%
17 $0
Q4 2017

Feb 14, 2018
SELL
$2.47 - $3.34 $349,450 - $472,536
-141,478 Reduced 68.98%
63,621 $170,000
Q3 2017

Nov 14, 2017
BUY
$3.12 - $3.65 $639,908 - $748,611
205,099
205,099 $654,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email